Translational Evaluation of Combined Immunotherapeutic Strategies and Advanced Supportive Care in Reducing Treatment-Related Toxicities Among Patients with Solid Malignancies

Background: Immune checkpoint inhibitors and combination immunotherapeutic regimens have substantially improved survival outcomes across advanced solid malignancies. However, treatment-related toxicities—particularly immune-related adverse events (irAEs)—frequently compromise therapeutic continuity, adherence, quality of life, and clinical benefit. Objective: This translational investigation evaluates whether integrating immunotherapy with a structured, multidisciplinary advanced supportive care framework reduces treatment-associated toxicities. Methods: A prospective multicenter longitudinal cohort study was conducted across accredited Type B hospitals in Indonesia, enrolling 500 patients with histologically confirmed advanced solid malignancies receiving PD-1/PD-L1-based immunotherapy or chemo-immunotherapy. All participants received standardized early toxicity surveillance, personalized nutritional optimization, and structured psychosocial support. Toxicity was graded using CTCAE v5.0. Outcomes were compared against institutionally established historical benchmarks derived from 412 comparable patients treated at participating centers during 2021–2022 prior to protocol implementation. Analytical approaches included mixed-effects regression, Kaplan–Meier estimation, multivariate logistic regression, and effect-size estimation with 95% confidence intervals. Results: Severe (grade ≥3) treatment-related toxicity occurred in 18.0% of patients, representing a 30.8% relative reduction from the historical benchmark of 26.0% (risk difference −8.0%, 95% CI −12.1% to −3.9%, p<0.001). Hospitalization rate was 22.0% (27.9% relative reduction from benchmark, p<0.001). Treatment adherence (≥85% planned cycles completed) was 85.6% versus 72.3% historically (p<0.001). Early toxicity monitoring (β = −0.41, 95% CI −0.58 to −0.24, p<0.001), nutritional optimization (β = −0.36, 95% CI −0.52 to −0.20, p<0.001), and psychosocial support (β = −0.29, 95% CI −0.45 to −0.10, p = 0.003) were independent protective predictors. Conclusion: Integrated proactive supportive care significantly ameliorates toxicity burden and improves tolerability. Systematic implementation alongside immunotherapy is recommended to optimize outcomes in routine oncology practice.

Authors

Institutions

Publication Details

Journal
Journal of Analytical Oncology
Published
2026-11-14
DOI
https://doi.org/10.30683/1927-7229.2026.15.11
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Translational Evaluation of Combined Immunotherapeutic Strategies and Advanced Supportive Care in Reducing Treatment-Related Toxicities Among Patients with Solid Malignancies

Agussalim Agussalim
Journal of Analytical Oncology
Cancer Immunotherapy and Biomarkers
article

Translational Evaluation of Combined Immunotherapeutic Strategies and Advanced Supportive Care in Reducing Treatment-Related Toxicities Among Patients with Solid Malignancies

Agussalim Agussalim
article en

Abstract

Background: Immune checkpoint inhibitors and combination immunotherapeutic regimens have substantially improved survival outcomes across advanced solid malignancies. However, treatment-related toxicities—particularly immune-related adverse events (irAEs)—frequently compromise therapeutic continuity, adherence, quality of life, and clinical benefit. Objective: This translational investigation evaluates whether integrating immunotherapy with a structured, multidisciplinary advanced supportive care framework reduces treatment-associated toxicities. Methods: A prospective multicenter longitudinal cohort study was conducted across accredited Type B hospitals in Indonesia, enrolling 500 patients with histologically confirmed advanced solid malignancies receiving PD-1/PD-L1-based immunotherapy or chemo-immunotherapy. All participants received standardized early toxicity surveillance, personalized nutritional optimization, and structured psychosocial support. Toxicity was graded using CTCAE v5.0. Outcomes were compared against institutionally established historical benchmarks derived from 412 comparable patients treated at participating centers during 2021–2022 prior to protocol implementation. Analytical approaches included mixed-effects regression, Kaplan–Meier estimation, multivariate logistic regression, and effect-size estimation with 95% confidence intervals. Results: Severe (grade ≥3) treatment-related toxicity occurred in 18.0% of patients, representing a 30.8% relative reduction from the historical benchmark of 26.0% (risk difference −8.0%, 95% CI −12.1% to −3.9%, p<0.001). Hospitalization rate was 22.0% (27.9% relative reduction from benchmark, p<0.001). Treatment adherence (≥85% planned cycles completed) was 85.6% versus 72.3% historically (p<0.001). Early toxicity monitoring (β = −0.41, 95% CI −0.58 to −0.24, p<0.001), nutritional optimization (β = −0.36, 95% CI −0.52 to −0.20, p<0.001), and psychosocial support (β = −0.29, 95% CI −0.45 to −0.10, p = 0.003) were independent protective predictors. Conclusion: Integrated proactive supportive care significantly ameliorates toxicity burden and improves tolerability. Systematic implementation alongside immunotherapy is recommended to optimize outcomes in routine oncology practice.

Journal of Analytical OncologyVol. 15
Kementerian Kesehatan Republik Indonesia (ID)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon